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Abstract
Type 2 diabetes (T2D) has been linked with increased intestinal permeability,
but the clinical significance of this phenomenon remains unknown. The objec-
tive of this study was to investigate the potential link between glucose control,
intestinal permeability, diet and intestinal microbiota in patients with T2D.
Thirty-two males with well-controlled T2D and 30 age-matched male controls
without diabetes were enrolled in a case–control study. Metabolic parameters,
inflammatory markers, endotoxemia, and intestinal microbiota in individuals
subdivided into high (HP) and normal (LP) colonic permeability groups, were
the main outcomes. In T2D, the HP group had significantly higher fasting
glucose (P = 0.034) and plasma nonesterified fatty acid levels (P = 0.049)
compared with the LP group. Increased colonic permeability was also linked
with altered abundances of selected microbial taxa. The microbiota of both
T2D and control HP groups was enriched with Enterobacteriales. In conclu-
sion, high intestinal permeability was associated with poorer fasting glucose
control in T2D patients and changes in some microbial taxa in both T2D
patients and nondiabetic controls. Therefore, enrichment in the gram-negative
order Enterobacteriales may characterize impaired colonic permeability prior
to/independently from a disruption in glucose tolerance.
ª 2018 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
The Physiological Society and the American Physiological Society.
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Introduction
Impaired barrier function has been hypothesized to lead
to the increased uptake of antigens of both dietary and
bacterial origin from the intestinal lumen into the circu-
lation, activating the innate immune system (Cani and
Everard 2016). Animal studies suggest that gut micro-
biota composition and diet may be key factors.
Increased fat content of the diet is associated with dys-
biosis and increased circulating lipopolysaccharide (LPS),
called metabolic endotoxemia and this has been associ-
ated with changes in the gut barrier function in mice
(Cani et al. 2008, 2009; Kim et al. 2012). Increased cir-
culating LPS and bacteria have been reported (Creely
et al. 2007; Amar et al. 2011; Sato et al. 2014), in addi-
tion to well established dysbiosis in T2D patients (Larsen
et al. 2010; Wu et al. 2010; Qin et al. 2012; Zhang et al.
2013; Remely et al. 2014, 2016; Lambeth et al. 2015;
Lippert et al. 2017). The gram-negative bacterial cell
membrane component, LPS, is a potent ligand of the
TLR-4 receptor. TLR-4 activation leads to increased
levels of proinflammatory cytokines, such as TNF-a and
interleukins, and this systemic low-grade inflammation is
associated with insulin resistance (Cani et al. 2007).
Administering LPS to animals and humans increases
inflammatory markers and insulin resistance, corroborat-
ing a role for LPS in metabolic diseases characterized by
low-grade inflammation (Cani et al. 2007; Andreasen
et al. 2010, 2011).
Impaired intestinal barrier function is suggested to be
implicated in gastrointestinal and metabolic diseases, such
as celiac disease, nonalcoholic fatty liver disease, and type
2 diabetes (T2D) (de Kort et al. 2011; Odenwald and
Turner 2013; Cox et al. 2017). In a recent pilot study,
T2D patients were found to have increased intestinal per-
meability (measured by urinary recovery of 51Cr-EDTA)
compared to healthy age-, sex-, and BMI-matched sub-
jects with small intestinal permeability correlating posi-
tively with circulating inflammatory markers (Horton
et al. 2014). However, there were no associations between
intestinal permeability and diet, anthropometrics or
markers of metabolic control. Similarly, in a larger study
a derived permeability risk score was higher in T2D
patients compared to healthy controls (Cox et al. 2017).
However, T2D patients and healthy individuals were not
matched for BMI, age, or sex in this latter study (Cox
et al. 2017).
However, it remains unclear what initiates this
increased intestinal permeability. Moreover, to date, the
link between intestinal permeability, oral antidiabetic
drugs (e.g., metformin), biochemical indices, diet, and
intestinal microbiota composition have not been thor-
oughly investigated.
In our previous work, we established that intestinal
permeability in males with T2D was significantly higher
than that of age-, sex-, and BMI-matched healthy con-
trols, however, the true clinical significance of this finding
remains to be established in vivo (Horton et al. 2014).
There is considerable variation in intestinal permeability
with a proportion of T2D patients having intestinal per-
meability within what would be considered the healthy
range, and similarly healthy individuals living with intesti-
nal permeability values within the pathological range. For
this reason, it is too simplistic to conclude that impaired
permeability can be implicated in the etiology of T2D in
all patients. In order to investigate this phenomenon, a
group of T2D patients and age-matched controls without
diabetes were split into impaired intestinal permeability
(high, HP) and normal permeability (low, LP) groups
based on the upper 95% CI cut-off of 1.58% for colonic
permeability using the 51Cr-EDTA intestinal permeability
test data already established in healthy insulin-sensitive
individuals (Horton et al. 2014). The phenotypes of the
colonic HP and LP groups were then compared in order
to elucidate any potential link between intestinal perme-
ability, gut bacterial profile, and systemic metabolism.
Methods
This was a case–control study designed to investigate the
role of intestinal bacteria and intestinal permeability in
T2D patients and age-matched control subjects without
diabetes. The protocol was approved by the Central Lon-
don NRES Committee (REC reference no. 11/LO/1141)
and the University of Surrey Ethics Committee and was
conducted according to the declaration of Helsinki.
Subjects
Thirty-two males with T2D and 30 males without dia-
betes (control subjects) were recruited through primary
care and volunteer databases at the University of Surrey
in 2012 and 2013. T2D had previously been diagnosed by
the general practitioner of the participants. Women were
excluded from this initial study due to the potential effect
of the menstrual cycle on outcome measures in addition
to the contraindication of administration of a radioactive
tracer (51Cr-EDTA) to healthy females who may be of
child bearing age. All subjects provided written informed
consent. Exclusion criteria included use of antibiotics in
the previous 3 months, use of anti-inflammatory medica-
tions (except a low-dose aspirin (75 mg/day)), diuretics,
inflammatory bowel disease, celiac disease, and irritable
bowel disease. Mild dyslipidemia and hypertension
were not considered reasons for exclusion. Renal function
was tested (eGFR > 60) to ensure suitability for the
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51Cr-EDTA intestinal permeability test. The T2D patient
group and control group were each split into HP and LP
groups with a cut-off value of 1.58% urinary 51Cr-EDTA
recovery (6–24 h after administration of the label).
Dietary intakes
Subjects were instructed to avoid probiotic food items,
fermented dairy such as yogurt and cheese in addition to
prebiotic supplements for 2 weeks before the test day, this
was assessed by a 7-day diet diary. Amounts were esti-
mated using normal household measurements. The diet
diaries were analyzed in DietPlan6 (Forestfield Software
Ltd, Horsham, UK).
Fecal sample collection
Subjects collected fecal samples at home using universal
sterile polystyrene containers. Fecal samples were initially
stored at 20°C and subsequently at 80°C for long-
term storage.
Blood pressure, anthropometrics, and
biochemistry
After having emptied their bladder, body weight, and
body composition was measured by bioimpedance (Tan-
ita, Arlington Heights, IL, USA). Waist circumference was
measured at the level of the naval with a tape measure.
Blood pressure was measured after 5-min rest and the
mean of three readings calculated (Omron MX3 Plus,
Omron Healthcare Europe, Milton Keynes, United King-
dom). A fasting blood sample (8 mL) was collected after
a 10-hour overnight fast at the CEDAR center of the
Royal Surrey County Hospital. Blood was collected into
EDTA tubes, serum tubes containing clotting activator
and pyrogen-free tubes for measurements of HbA1c, glu-
cose, insulin, inflammatory markers, lipids, and LPS.
Blood samples were centrifuged at 3000g at 4°C for
10 min and serum and plasma stored at 20°C or 80°C
as appropriate.
Intestinal permeability
Intestinal permeability was measured by 24 h urinary
excretion of orally administered 51Cr-EDTA as previously
described (Horton et al. 2014). The 51Cr-EDTA was
administered after an overnight fast and patients were
asked to collect all their urine in the next 24 h. The urine
was collected into one container for the first 6 h and into
a separate container for 6–24 h. The first 6 h of collection
is considered to represent small intestinal permeability
and the 6–24 h 51Cr-EDTA recovery represents the
colonic permeability. The adequacy of the urine collection
was assessed using questionnaires on the completeness of
the urine collection.
Biochemical analyses
Whole blood glucose concentrations were measured
immediately using the glucose oxidase method on the YSI
2300 STAT Plus (YSI Life Sciences, Fleet, UK) with a pre-
cision of 2% (or 0.2 mmol/L) and a linear range up to
50 mmol/L. The average intra-assay CV was 4.8% and
inter-assay CV was 5.8%. Plasma insulin was analyzed in
duplicate using a radioimmunoassay (Millipore, Billerica,
MA) with an interassay CV of 12.6% and average intra-
assay CV of 7.7%. The sensitivity of the assay was
16.29 pmol/L. Serum hsCRP and HbA1c were measured
by an accreditated laboratory, the Surrey Pathology Part-
nership and serum IL-6 and TNF-a were measured using
a Luminex platform and Biorad bio-plex kits and soft-
ware. The limit of detection was 0.03 mg/L for hsCRP,
5 pg/mL for TNF-a and 0.7 pg/ml for IL-6. Triglycerides
TAGs, total cholesterol, HDL cholesterol, and nonesteri-
fied fatty acids (NEFA) were measured on an ILab650
using commercially available kits (Randox Laboratories,
UK, and Instrumentation Laboratory, UK). Average intra-
assay CVs were 1.4%, 1.9%, 0.6% and 1.0% and inter-
assay CVs were 1.9%, 3.0%, 1.1% and 1.8% and detection
limits were 0.1 mmol/L, 0.22 mmol/L, 0.189 mmol/L,
0.072 mmol/L for TAGs, total cholesterol, HDL choles-
terol, and NEFA, respectively. LDL cholesterol concentra-
tion was calculated using the Friedewald formula. LPS
was measured in duplicate using Endosafe-MCS (Charles
River Laboratories, Lyon, France) as previously described
(Everard et al. 2012). Samples were diluted from 1/20 to
1/200 and the samples were validated for recovery and
coefficient of variation determination. The limit of detec-
tion was 0.005 EU/mL. Serum LPS binding protein (LBP)
and sCD14 concentrations were measured using a solid-
phase enzyme-linked immunosorbent assays (ELISA)
according to the manufacturer’s instructions (Hycult
Biotechnology, Uden, the Netherlands). Sera were diluted
1/10 with the appropriate buffer and homogenized by
vortex before further dilution to 1/200 (sCD14) and 1/
1000 (LBP). Detection limits were 4.4 and 1.56 ng/mL
and the average intra-assay CVs were 3.9% and 8.5% and
inter-assay CVs were 19.6% and 15.5% for LBP and
sCD14, respectively.
DNA extraction
DNA was extracted from defrosted fecal samples using
the PowerFecalTM DNA Isolation Kit (MO BIO Laborato-
ries Inc., Carlsbad, CA, USA) according to the
ª 2018 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
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manufacturer’s instructions. The DNA concentration and
quality were measured by NanoDrop 2000 (Thermo Sci-
entific) and Qubit 2.0 fluorometer (Invitrogen). Samples
with a DNA concentration >50 ng/lL was used for
sequencing. Due to unsuccessful DNA extraction for some
samples, bacterial data are only available for a subset of
T2D patients (n = 23) and controls (n = 27).
Amplification and high-throughput
sequencing
DNA amplification and sequencing were performed as
previously described (Ellis et al. 2013). Briefly, the V4
and V5 region of the bacterial 16S rRNA gene was ampli-
fied from extracted DNA with universal primers (U515F:
50-GTGYCAGCMGCCGCGGTA and U927R: 50-CCCGY-
CAATTCMTTTRAGT). Forward fusion primers consisted
of the GS FLX Titanium primer A and the library key
(50 -CATCTCATCCCTGCGTGTCTCCGACTCAG) together
with one of a suite of sixteen 10-base multiplex identifiers
(MIDs 1–16) (Roche Diagnostics Ltd, UK). Reverse fusion
primers included the GS FLX Titanium primer B and the
library key (50-CCTATCCCCTGTGTGCCTTGGCAGTCT-
CAG). Amplification was performed with FastStart HiFi
Polymerase (Roche Diagnostics Ltd, UK) using the fol-
lowing cycling conditions: 94°C for 3 min; 30 cycles of
94°C for 30 sec, 55°C for 45 sec, 72°C for 1 min; fol-
lowed by 72°C for 8 min. Ampure XP magnetic beads
(Beckman Coulter) were used for purification of ampli-
cons. Amplicon concentration was assessed using the flu-
orescence-based Picogreen assay (Invitrogen) and
concentrations normalized before pooling. Amplicon
pools were immobilized and amplified on beads by emul-
sion PCR using Lib-L emPCR kits (Roche Diagnostics
Ltd, UK). Unidirectional sequencing from the forward
primer was performed on the 454 GS FLX Titanium plat-
form according to the manufacturer’s instructions (Roche
Diagnostics Ltd, UK).
Quantification of bacterial groups by
quantitative PCR
Total bacteria and the bacterial groups Bifidobacterium,
Roseburia, Lactobacillus, Enterobacteriaceae, Clostridium
leptum, and Clostridium coccoides groups were quantified
by quantitative PCR (qPCR) on a QuantStudio 7 Flex
Real-time system (Life technologies, USA). The qPCR pri-
mers are described in Table 1. A typical 20 lL qPCR
reaction contained 0.3 lmol/L of each (forward and
reverse) primer, 10 lL GoTaq qPCR master mix, 7.8 lL
of nuclease-free water and 5–20 ng of template genomic
DNA extract. The qPCR cycling protocol consisted of 19
initial denaturation cycle at 95°C for 2 min followed by
409 denaturation at 95°C for 15 sec, annealing at 55°C
for 30 sec, and extension at 72°C for 30 sec; fluorescence
was measured after each cycle and 19 dissociation 60–
95°C.
Quantitation of each target in the samples was deter-
mined based on a standard curve of each target using
purified target DNA template. A 10-fold dilution series
ranging from 1 9 104–1 9 108 copies of each target gene
was prepared in nuclease-free water and analyzed in trip-
licate. The test samples were analyzed in 96-well plates
(MicroAMP Optical plates, Life Technologies, USA),
along with the standard. The qPCR software generated
the standard curve (based on the average of each stan-
dard) and computed the template concentrations. The
amplification of a single product by the primer sets used
Table 1. Primers used for qPCR.
Target Primer name Sequence Product bp
Clostridium leptum subgroup C-leptF GCACAAGCAGTGGAGT 239
C-leptR CTTCCTCCGTTTTGTCA
Clostridium coccoides subgroup C-cocF AAATGACGGTACCTGACTAA 440
C-cocR CTTTGAGTTTCATTCTTGCGAA
Roseburia RosF TACTGCATTGGAAACTGTCG 230
RosR CGGCACCGAAGAGCAAT
Lactobacillus group LacF AGCAGTAGGGAATCTTCCA 341
LacR CACCGCTACACATGGAG
Bifidobacterium BifF GCGTGCTTAACACATGCAAGTC 126
BifR CACCCGTTTCCAGGAGCTATT
All bacteria UnivF TCCTACGGGAGGCAGCAGT 466
UnivR GACTACCAGGGTATCTAATCCTGTT
Enterobacteriaceae EcoF CATTGACGTTACCCGCAGAAGAAGC 190
EcoR CTCTACGAGACTCAAGCTTGC
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was confirmed by analysis of the dissociation profile of
each target and agarose gel electrophoresis of a standard
PCR reaction using each primer set, the same cycling
conditions and DNA template.
Bioinformatics and statistical analysis
The sequences were processed in Qiime (Caporaso et al.
2010) using the AmpliconNoise (Quince et al. 2011)
pipeline that utilizes flowgram information of the
sequences to correct for errors. The samples were demul-
tiplexed by exact matching of both barcode and primer
and the sequences filtered and trimmed based on identifi-
cation of low-quality signals (Quince et al. 2009). The
filtered flowgrams were clustered to remove platform-
specific errors and converted into sequences using the
PyroNoise algorithm. The sequences had barcodes and
degenerate primers removed prior to trimming at 500
base pairs (bp). They were then further clustered by Seq-
Noise to remove PCR single base errors. In the final step,
the Perseus algorithm was used to identify chimeras. The
denoised sequences were classified using the standalone
RDP classifier (Wang et al. 2007). From this, taxa fre-
quencies at five different levels: Phylum, Class, Order,
Family and Genus; were calculated. Additionally, a non-
supervised approach was used, operational taxonomic
units (OTUs) were generated at 3% divergence following
pair-wise global sequence alignment and hierarchical clus-
tering with an average linkage algorithm. To improve res-
olution at the OTU level, sequences were also compared
with databases at the NCBI website (http://blast.ncbi.nlm.
nih.gov/Blast.cgi). Further statistical analyses were per-
formed in R using the tables and data generated as above
as well as the meta-data associated with the study. For
community analyses (including alpha and beta diversity
analyses and permutation ANOVA using distance mea-
sures (adonis function)) we used the vegan (http://cran.r-
project.org/web/packages/vegan/) package. To calculate
Unifrac distances (that account for phylogenetic close-
ness), we used the phyloseq (McMurdie and Holmes
2013), ape (Paradis et al. 2004), and phangorn (Schliep
2011) packages. To determine significant differences in
bacterial abundances between the groups, we used DESeq-
DataSetFromMatrix() function from DESeq package with
a significance value cut-off of 0.05. This function allows
negative binomial GLM fitting (as abundance data from
metagenomic sequencing is overdispersed) and Wald
statistics for abundance data and identifies species with
log-fold changes between different conditions. General
scripts and tutorials for the above analyses are available at
http://userweb.eng.gla.ac.uk/umer.ijaz#bioinformatics.
Data are presented as mean and SD or median and
interquartile range as appropriate. T2D, overweight/
obese (OW), and normal weight (NW) groups were
compared using a one-way ANOVA with Sidak correc-
tions for multiple comparisons using OW controls as
the control group. Nonparametric data were tested
using the Kruskal–Wallis test with Dunn’s post hoc
tests. Pair-wise comparisons of HP and LP groups were
performed using unpaired t tests for parametric data
and Mann–Whitney tests for nonparametric data. RT
qPCR total bacteria values are presented as log10 of val-
ues. Values for bacterial groups were normalized to
total bacteria. Where appropriate, p-values were
adjusted for multiple corrections using the Benjamini–
Hochberg method (Benjamini and Hochberg 1995).
Data were analyzed in GraphPad Prism 6, SPSS 22 and
R. The level of significance was set at P < 0.05.
Results
In an exploratory analysis the 30 nondiabetic controls
were split into two groups: NW controls (n = 14)
matched on age and OW controls (n = 16) matched to
the diabetes patients on age and BMI. The anthropomet-
ric, dietary, and clinical data for T2D, OW controls, and
NW controls are shown in Table 2.
Six of the T2D patients were diet/exercise controlled;
the remaining 26 patients were on various oral antidia-
betic medications (n): Metformin (12), sulfonylureas (1),
DPP4 inhibitor (1), metformin and DPP4 inhibitor (4),
metformin and sulfonylureas (5), sulfonylureas and DPP4
inhibitor (1), metformin, sulfonylureas, and DPP4 inhibi-
tor (1), and metformin, DPP4 inhibitor and thiazolidine-
dione (1). All patients had been on a stable treatment for
at least 3 months prior to taking part in the study. Other
medications taken by T2D patients included low lipid
lowering medications (mainly statins) (21), blood pres-
sure lowering medications (16), omeprazole (3), levothy-
roxine (2), fenofibrates (2), Betahistine hydrochloride (1)
and medications for incontinence (2), benign prostate
hyperplasia (3), fungal infection (2), hay fever (2), asthma
(inhaler) (1), and depression (1).
One NW and one OW control subject were taking sta-
tins and two OW controls were taking blood pressure
medication. Other medications used in the control groups
were asthma inhalers (4), benign prostate hyperplasia
medication (1), antidepressant (1), mysoline (1), epilim
(1), becotide (1), beconase (1), qvar (1), and dutasteride
(1).
Biochemical outcomes
Fasting glucose was significantly higher in the T2D
patients compared with OW controls. HOMA %B was
significantly higher in OW controls compared with both
ª 2018 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
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T2D patients and NW controls (P = 0.0013 and
P = 0.0268, respectively), whereas fasting insulin concen-
trations, insulin sensitivity (HOMA %S), and insulin
resistance (HOMA IR) were only significantly different
between control groups (P = 0.0418, P = 0.0385, and
P = 0.0383, respectively).
Serum total and LDL cholesterol concentrations were
lower and NEFA concentrations higher in T2D patients
compared with OW controls (P < 0.0001, P < 0.0001,
and P = 0.0092, respectively). HDL cholesterol was signif-
icantly lower in OW controls than in NW controls
(P = 0.0325). LBP (P = 0.0055) and hsCRP
Table 2. Anthropometric characteristics, clinical parameters, and dietary intakes in T2D patients, overweight (OW), and normal weight (NW)
controls. Data are presented as means (SD) or medians (interquartile range).
T2D Control OW Control NW P-value
n 32 16 14 –
Age (years) 57.9 (6.2) 57.3 (7.2) 56.6 (7.4) ns
Body weight (kg) 88.4 (12.8) 91.2 (8.0) 68.3 (6.1)1 <0.0001
BMI (kg/m2) 28.4 (25.8–30.8) 28.3 (26.7–29.8) 22.5 (20.4–23.6)1 <0.0001
Body fat (%) 25.9 (4.9) 26.2 (4.6) 17.6 (5.0)1 <0.0001
Waist circumference (cm)2 102.1 (10.4) 103.3 (9.4) 84.7 (6.3)1 <0.0001
Fasting glucose (mmol/L) 6.0 (5.3–7.2)1 4.7 (4.4–5.0) 4.4 (4.2–4.9) <0.0001
Fasting insulin (pmol/L) 80.1 (49.3–110.0) 59.9 (47.1–107.8) 41.6 (35.0–52.0)1 0.0032
HOMA2%B 102.0 (43.6)1 151.5 (59.3) 109.8 (22.3)1 0.0023
HOMA2%S 55.8 (41.8–84.4) 81.6 (42.7–102.7) 116.3 (91.5–141.8)1 0.0012
HOMA2 IR 1.8 (1.2–2.4) 1.2 (1.0–2.4) 0.9 (0.7–1.1)1 0.0011
HbA1c (mmol/mol) 49.0 (9.5) n/a n/a –
HbA1c (%) 6.6 (0.9) n/a n/a –
BP sys (mm Hg)2 135 (11) 133 (12) 118 (8)1 <0.0001
BP dia (mm Hg)2 84 (7) 86 (7) 78 (8)1 0.0052
Total Cholesterol (mmol/L) 3.4 (0.9)1 5.1 (1.0) 5.1 (0.9) <0.0001
HDL Cholesterol (mmol/L) 1.0 (0.3) 1.1 (0.3) 1.4 (0.4)1 0.0009
LDL Cholesterol (mmol/L) 2.0 (0.8)1 3.5 (0.8) 3.3 (0.7) <0.0001
NEFA (mmol/L) 0.67 (0.25)1 0.45 (0.21) 0.47 (0.25) 0.0047
TAGs (mmol/L) 1.00 (0.40) 1.03 (0.45) 0.93 (0.22) ns
51Cr-EDTA 0–6 h (%) 1.6 (0.9) 1.4 (0.7) 1.5 (0.6) ns
51Cr-EDTA 6–24 h (%) 1.4 (1.1–2.1) 1.3 (0.9–1.6) 1.6 (1.3–1.9) ns
51Cr-EDTA total (%) 3.4 (1.6) 2.7 (1.0) 3.0 (0.9) ns
LPS (EU/mL)2 0.63 (0.48–1.15) 0.49 (0.37–0.85) 0.84 (0.73–1.21)1 ns
LBP (lg/mL) 10.8 (8.7–13.0) 12.1 (10.7–13.4) 9.0 (7.4–10.2)1 0.0112
sCD14 (lg/mL) 1.0 (0.8–1.2) 1.0 (0.8–1.3) 0.9 (0.8–1.1) ns
hsCRP (mg/L) 1.36 (0.55–2.06) 1.32 (0.81–3.35) 0.44 (0.26–1.23)1 0.0194
IL-6 (pg/mL) 11.6 (7.0–13.9) 19.6 (7.4–36.0) 7.0 (5.5–18.4) ns
TNF-a (pg/mL) 13.0 (5.0–22.3) 7.0 (5.0–28.9) 6.0 (5.0–7.3) ns
Shannon index3 3.294 (2.981–3.580) 3.186 (3.139–3.387) 3.348 (3.037–3.695) ns
Observed Richness3 76.71 (66.55–85.07) 78.80 (63.91–96.15) 85.57 (68.58–104.80) ns
Pielou’s evenness3 0.706 (0.657–0.751) 0.677 (0.681–0.707) 0.696 (0.635–0.749) ns
Energy intake (kJ/day) 8672 (2054) 9939 (1710) 9662 (2323) ns
Total carbohydrate (% of energy) 41.4 (7.6) 39.8 (5.2) 45.3 (6.8) ns
Sugars (% of energy) 14.6 (5.3) 17.2 (4.5) 19.9 (5.4) 0.0086
Protein (% of energy) 16.4 (3.1) 15.1 (2.0) 14.8 (1.6) ns
Total fat (% of energy) 36.7 (5.6) 39.9 (5.5) 34.6 (5.8)1 0.0418
Saturated fat (% of energy) 12.3 (2.5)1 14.6 (3.1) 12.9 (3.1) 0.0279
Alcohol (g/day) 9.3 (0.4–25.5) 13.1 (5.9–22.6) 12.2 (9.4–19.1) ns
Dietary fiber (g/day) 22 (5) 23 (7) 27 (12) ns
Sodium (mg/day) 3138 (834) 3398 (777) 2833 (713) ns
n/a, not measured. NW group, n = 13 for dietary data. BP, blood pressure (sys: systolic, dia: diastolic).
1
Significantly different from OW Control group (P < 0.05).
2
n = 31 for the T2D group.
3
n = 20, n = 13 and n = 12 for the T2D, OW and NW group, respectively.
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concentrations (P = 0.0163) were higher, but LPS concen-
trations were lower (P = 0.0432) in OW controls com-
pared with NW controls. There were no significant
differences between groups in TGs, sCD14, IL-6, and
TNF-a concentrations, although IL-6 concentrations
tended to be higher in the OW controls compared to
NW controls (P = 0.0669) (Table 2).
Intestinal permeability
There were no significant differences in the recovery of
51Cr-EDTA in urine between groups (Table 2).
Dietary assessment
No significant differences in energy intake between groups
were observed (Table 2). However, T2D patients reported
significantly lower sugar intake (g/day), total fat (g/day)
and saturated fat (g/day and percentage of energy) intakes
than OW controls (P = 0.0252, P = 0.0139, P = 0.0013,
and P = 0.0156, respectively). Fat percentage of energy
was higher in the OW control group than in the NW
control group (P = 0.0286).
Bacterial community structure
Due to unsuccessful DNA extraction (DNA concentration
<50 ng/mL) for a number of samples, the qPCR dataset
consisted of n = 23 for the T2D group, n = 15 for the
OW group and n = 12 for the NW group. After exclud-
ing samples with <500 bp, the next-generation sequencing
dataset consisted of 20, 13, and 12 for the T2D, OW, and
NW group, respectively.
Consistent with previous reports the predominating
phyla were Bacteroidetes and Firmicutes followed by
unclassified bacteria and Proteobacteria. There were no sig-
nificant differences in alpha-diversity, richness, or evenness
indices between groups (Table 2). Ordination plots did not
show any clustering of T2D patients and control groups
(Fig. 1A and B). However, comparison of bacterial abun-
dances showed significant differences at the order, genus
and OTU levels with higher abundance of Enterobacteriales,
unclassified Enterobacteriaceae, and Escherichia coli (OTU
5), respectively, in T2D patients (Fig. 1C–E). No significant
differences between groups were found at the phylum,
class, or family levels in the next-generation sequencing
dataset.
Real-time PCR measurements showed that Lactobacillus
spp., C. leptum, and C. coccoides levels were significantly
higher in T2D patients compared with OW controls
(Fig. 2). Total bacteria was significantly higher in NW
controls than in OW controls, but no other significant
differences between OW and NW control groups were
found. However, there was a trend for a difference in
Enterobacteriaceae levels with lowest levels observed in
NW controls and highest levels in the T2D group.
Correlations between clinical outcomes
Intestinal permeability did not correlation with clinical
outcomes in any group (Fig. 3). However, in T2D
patients LPS correlated with beta-cell function (r = 0.52,
adj. P = 0.0025) and fasting glucose (r = 0.36, adj.
P = 0.049), whereas hsCRP correlated with LBP (r = 0.52,
adj. P = 0.0019), IL-6 (r = 0.36, adj. P = 0.0416), and
BMI (r = 0.48, adj. P = 0.0034) and LBP correlated with
fasting glucose (r = 0.35, adj. P = 0.0488). Furthermore,
waist circumference and BMI correlated positively with
insulin resistance, TGs, and fasting insulin and inversely
with insulin sensitivity. Few significant correlations were
found in the control groups.
Comparison of high permeability and low
(normal) permeability groups
As the density of bacteria is highest in the colon we
explored whether clinical parameters, dietary intakes
(Tables 3 and 4) and intestinal bacterial abundances
(Fig. 4) differed between those with high and normal
colonic permeability. Time since diagnosis of diabetes was
similar in the LP and HP diabetes groups (mean:
4.6 years (range: 0.1–10 years) and 4.7 years (range: 0.5–
11 years), respectively).
Anthropometrics, biochemistry, and diet
T2D patients in the HP group had significantly higher
fasting glucose and NEFA concentrations than those in
the LP group. No significant differences in inflammatory
markers or dietary intakes were detected between groups,
although there were a trend toward a lower total carbohy-
drate intake and higher BMI in the HP group (Table 4).
In contrast, in the controls, the HP group had signifi-
cantly lower body weight, higher HDL cholesterol concen-
tration and lower total energy and absolute sugar, protein
and dietary fiber intakes than the LP group. Inflammatory
markers and other glucose tolerance markers did not dif-
fer between control LP and HP groups (Table 3).
Differences in intestinal bacterial
abundances
No significant differences in overall bacterial community
composition between LP and HP for both T2D and con-
trol groups were found (adonis analysis, P > 0.7). As for
bacteria abundances, the order Selenomonadales and
ª 2018 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
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Prevotella (OTU 14) were higher and Enterobacteriales
and an unclassified Ruminococcaceae (OTU 20) were
lower in the LP group compared to the HP T2D group.
In controls, Enterobacteriales and Blautia (OTU 50) were
enriched in the HP group. Accessions numbers for OTUs
are provided in Table 5.
Enterobacteriales enrichment therefore appears to char-
acterize high colonic permeability in both T2D patients
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Figure 1. Unweighted (A) and weighted (B) UniFrac distances in T2D patients and normal weight (NW) and overweight/obese (OW) controls.
There were significant differences between groups in the order Enterobacteriales, genus unclassified Enterobacteriaceae and Escherichia coli
(OTU 5) between normal weight (NW) controls (n = 12), overweight/obese (OW) controls (n = 13), and T2D patients (n = 20) (C–E). FDR
adjusted P-values are displayed in the header of the panels.
Figure 2. Total bacteria and selected bacterial groups were quantified by real-time qPCR (median, interquartile ranges, and min and max
values, n = 23, n = 15 and n = 12 for T2D, OW, and NW control groups, respectively). Although post hoc tests showed that total bacteria
were significantly higher in control NW compared to control OW (P = 0.030), there was only a trend toward a main effect (P = 0.0516) (A).
Abundances of Lactobacillus spp. and Clostridium leptum and Clostridium coccoides clusters were significantly different between groups
(P = 0.0062, P < 0.0001 and P < 0.0001, respectively) with significantly higher levels in T2D compared to control OW (P = 0.0183, P < 0.0001
and P = 0.004, respectively) (C, F and G). While Roseburia spp. and Bifidobacterium spp. did not differ between groups (P = 0.9835 and
P = 0.1660) (B and D), there was a trend toward a differences in Enterobacteriaceae between groups (P = 0.0504) (E).
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and healthy controls (Fig. 4). No significant differences at
the phylum level, in diversity, richness, evenness indices
(Table 6) or any of the bacterial groups measured by
qPCR between HP and LP groups were found (data not
shown).
Retrospective analysis: effect of metformin
on gut microbiota in diabetes patients
While this study was underway, several studies were pub-
lished indicating that metformin has a profound effect on
the gut microbiota composition in both animal and
human studies (Karlsson et al. 2013; Napolitano et al.
2014; Shin et al. 2014; Forslund et al. 2015; de la Cuesta-
Zuluaga et al. 2017). Although the study was not powered
to look at the effects of medications, an exploratory inves-
tigation into the effects of metformin was undertaken.
Bacterial data were available for seven nonmetformin-
treated patients and 13 metformin-treated patients. We
found no significant effect of metformin on overall
microbiota composition (P > 0.5, Fig. 5A). However, the
orders Enterobacteriales and Erysipelorichales, the family
Enterobacteriaceae and an unclassified Enterobactericeae at
the genus level and E. coli (OTU 5) at the species-like
level were significantly enriched following metformin
treatment (Fig. 5B–E). In contrast, the orders Selenomon-
adales and unclassified Clostridia, the families Peptostrep-
tococcaceae and Clostridiaceae 1, the genus Clostridium
cluster XI and three OTUs belonging to the Firmicutes in
addition to Sutterella (Proteobacteria) were decreased in
metformin-treated patients (Fig. 5B–E). No significant
differences were found in bacterial groups measured by
qPCR (data not shown) between metformin- and non-
metformin-treated patients.
There were no statistically significant differences in
intestinal permeability, biochemistry variables or dietary
intakes between metformin- and nonmetformin-treated
patients, although IL-6 and TNF-a tended to be higher
(IL-6: 12.9  1.6 vs. 7.9  1.3 pg/mL, P = 0.069; TNF-a:
13.0 (5.0–22.3) vs. 5.0 (5.0–13.0) pg/mL, P = 0.093) and
total cholesterol and LDL cholesterol tended to be lower
with metformin use (total cholesterol: 3.2  0.2 vs.
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Figure 3. Correlation heat maps showing associations (Kendall’s rank correlations) between clinical outcomes (adjusted for multiple testing).
Due to missing data for some participants, correlations coefficients were not calculated for waist circumference and LPS. Normal weight (NW)
controls: n = 12, overweight/obese (OW) controls: n = 13, and T2D patients: n = 20.
2018 | Vol. 6 | Iss. 7 | e13649
Page 10
ª 2018 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
The Physiological Society and the American Physiological Society.
Intestinal Permeability and Microbiota C. Pedersen et al.
3.9  0.3 mmol/L, P = 0.051; LDL cholesterol: 1.8  0.1
vs. 2.4  0.2 mmol/L, P = 0.074).
Discussion
In this study we have measured markers of glucose toler-
ance, inflammation, endotoxemia, intestinal permeability,
and intestinal bacterial community structure in the same
individuals, investigating for the first time whether there
is a potential link between intestinal permeability and glu-
cose control/inflammation in T2D, as a first translation
from the extensive and seemingly consistent animal litera-
ture. Our findings do not suggest strong links between
intestinal permeability and the microbiota, inflammation
and diet exist in T2D patients. Intestinal permeability did
not differ significantly between NW, OW, and T2D
patients, although it was numerically higher in T2D
patients. This is in contrast with our previous study
(Horton et al. 2014), however, a relatively large propor-
tion of the controls were found to be above the 95% CI
cut-off for “normal” total and colonic permeability estab-
lished in our previous work. Previously we established
“normal permeability” in those with “normal insulin sen-
sitivity” established by HOMA (mean HOMA IR of 1.0).
However, in this study, the nondiabetic group was
recruited to be a phenotypic match to the diabetes group
Table 3. Clinical outcomes in normal (LP) and high (HP) colonic permeability groups. Data are presented as means (SD) or median (interquar-
tile range).
T2D patients Controls
LP HP P-value LP HP P-value
n 19 13 – 19 11 –
51Cr-EDTA 6–24 h (%) 1.17 (0.99–1.36) 2.19 (1.81–3.10) <0.0001 1.16 (0.90–1.47) 1.87 (1.64–2.09) <0.0001
Age (years) 58.2 (6.3) 57.4 (6.2) ns 56.6 (7.0) 57.5 (7.9) ns
Weight (kg) 86.6 (12.7) 91.0 (12.9) ns 84.6 (13.6) 73.5 (10.7) 0.029
BMI (kg/m2) 27.5 (3.3) 29.7 (3.9) ns 26.6 (4.5) 24.2 (3.0) ns
Body fat (%) 25.0 (4.7) 27.4 (5.1) ns 22.7 (7.3)1 20.9 (4.7) ns
Waist circumference (cm) 100.1 (10.1)1 104.9 (10.6) ns 97.6 (14.0) 89.5 (6.9) ns
Blood pressure,
systolic (mm Hg)
135 (10)1 135 (12) ns 127 (10) 125 (16) ns
Blood pressure,
diastolic (mm Hg)
85 (6)1 84 (8) ns 82 (9) 82 (9) ns
HbA1c (mmol/mol) 47.4 (6.6) 51.2 (12.4) ns n/a n/a –
HbA1c (%) 6.5 (0.4) 6.8 (1.3) ns n/a n/a –
Fasting glucose (mmol/L) 5.8 (1.1) 6.7 (1.1) 0.034 4.7 (0.6) 4.6 (0.6) ns
Fasting insulin (pmol/L) 81.4 (47.9–111.7) 70.0 (50.3–132.2) ns 51.5 (41.9–77.7) 42.3 (35.6–53.4) ns
HOMA %B 112.5 (44.5) 86.7 (39.0) ns 127 (109–147) 111 (86–134) ns
HOMA %S 54.1 (41.8–87.2) 59.9 (35.2–85.1) ns 92.6 (61.1–111.5) 109.3 (88.3–140.6) ns
HOMA IR 1.88 (1.15–2.40) 1.67 (1.19–2.97) ns 1.08 (0.90–1.64) 0.91 (0.71–1.13) ns
Total cholesterol (mmol/L) 3.5 (1.0) 3.3 (0.7) ns 5.0 (1.0) 5.4 (0.7) ns
LDL cholesterol (mmol/L) 2.0 (0.9) 1.9 (0.6) ns 3.3 (0.8) 3.5 (0.7) ns
HDL cholesterol (mmol/L) 1.0 (0.2) 1.0 (0.3) ns 1.2 (0.4) 1.5 (0.4) 0.040
NEFA (mmol/L) 0.60 (0.22) 0.77 (0.26) 0.049 0.47 (0.20) 0.45 (0.28) ns
TAGs (mmol/L) 1.06 (0.44) 0.91 (0.32) ns 0.95 (0.79–1.13) 0.86 (0.73–1.03) ns
hsCRP (mg/L) 1.3 (0.6–1.7) 1.5 (0.5–4.4) ns 2.7 (6.0) 1.5 (1.5) ns
IL-6 (pg/mL) 8.5 (7.0–12.6) 13.3 (5.5–14.9) ns 7.0 (5.5–20.3) 19.6 (8.5–30.3) ns
TNF-a (pg/mL) 13.0 (5.0–22.3) 8.2 (5.0–17.7) ns 7.0 (5.0–13.0) 7.0 (5.0–13.0) ns
LPS (EU/mL) 0.93 (0.50–1.38) 0.49 (0.38–1.05)2 ns 0.68 (0.40–1.08) 0.84 (0.48–1.00) ns
LBP (lg/mL) 11.0 (3.1) 10.3 (4.7) ns 10.5 (7.6–13.3) 10.3 (9.0–11.5) ns
sCD14 (lg/mL) 1.03 (0.78–1.37) 0.94 (0.77–1.09) ns 0.88 (0.82–1.11) 1.11 (0.82–1.29) ns
Metformin (n/%) 14/73.7 9/69.2 – n/a n/a –
Statins (n/%) 14/73.7 7/53.8 – 1/5.3 1/9.1 –
BP medication (n/%) 10/52.3 8/61.5 – 2/10.5 0/0 –
Aspirin (n/%) 3/15.8 3/23.1 – 0/0 0/0 –
1
n = 18.
2
n = 12.
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and so had with a much broader range of background
insulin sensitivity, more representative of the general pop-
ulation. Fat intake was significantly higher in the OW
group compared with the T2D patients and a high-fat
diet has been demonstrated to induce gut barrier dysfunc-
tion (Cani et al. 2008; Stenman et al. 2012). The lower
sugar and fat intakes in T2D patients suggest they may
have modified their diet since being diagnosed with dia-
betes, however, very few significant correlations between
dietary intakes and microbial abundances were found in
the T2D group (data not shown).
Comparison of the LP and HP groups revealed that
high permeability was associated with lower Selenomon-
adales levels and Enterobacteriales enrichment of the
Table 4. Dietary intakes based on 7-day diet diaries (means (SEM) or median (interquartile range)).
T2D patients Controls
LP HP P-value LP HP P-value
n 19 13 18 11
Energy (kJ) 9187 (1849) 7921 (2176) ns 10476 (1818) 8733 (1796) 0.018
Dietary fiber (g/day) 23 (6) 20 (5) ns 25 (22–34) 17 (16–24) 0.022
Alcohol (g/day) 13 (13) 12 (12) ns 15 (9) 13 (9) ns
Sodium (mg/day) 3249 (947) 2975 (635) ns 3322 (3086–3659) 2530 (1903–3580) ns
Total carbohydrate
(% of energy)
41.7 (9.0) 40.8 (5.1) ns 43.0 (7.0) 41.1 (5.6) ns
Sugars (% of energy) 15.4 (6.1) 13.5 (3.7) ns 19.3 (5.4) 17.0 (4.2) ns
Protein (% of energy) 15.8 (3.3) 17.2 (2.5) ns 15.2 (2.2) 14.6 (1.1) ns
Total fat (% of energy) 36.5 (6.0) 37.0 (5.3) ns 36.8 (6.3) 38.8 (5.9) ns
Saturated fat (% of energy) 12.3 (2.2) 12.1 (2.9) ns 13.3 (2.5) 14.7 (4.1) ns
Alcohol (% of energy) 3.8 (0–8.7) 3.1 (0.3–6.5) ns 4.2 (2.8) 4.3 (3.1) ns
Figure 4. Differences in abundances of several bacteria in type 2 diabetes patients (A and B) and controls (C and D) colonic HP and LP groups
were found. Taxonomic annotation and adjusted P-values are displayed in the headers. T2D HP: n = 9, T2D LP: n = 11, Control HP: n = 9,
Control LP: n = 16.
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intestinal microbiota, higher fasting glucose (as a poten-
tial indicator of impaired hepatic glucose output) and ele-
vated serum NEFA (as a proxy for adipose tissue
dysfunction) in T2D. However, in contrast to the animal
literature and our recent pilot study (Horton et al. 2014),
there was no association between intestinal permeability
and inflammatory markers. The patients in this study
have a better glucose control than those in the pilot study
based on fasting glucose, HbA1c and HOMA-IR. This
could potentially have made it more difficult to detect
associations between outcomes. The use of medications
may also have confounded the association between
inflammatory markers and intestinal permeability and
partly explain the lack of a significant difference in
intestinal permeability between T2D patients and controls
in this study. A higher proportion of T2D patients (>80%
vs. 65%) was taking antihyperglycemic medication than
in the pilot study by Horton et al. (2014). Also, more
than 50% of the participants were taking of lipid lowering
and/or blood pressure lowering medications in this study.
Statins and hypotensive medications have been demon-
strated to have anti-inflammatory effects (Andrzejczak
et al. 2007; Wang et al. 2011).
Although BMI and body fat percentage were not signif-
icantly different between HP and LP groups, the slightly
higher BMI and body fat percentage in the T2D HP
group may contributed to the elevated fasting glucose and
NEFA, independently from the increased intestinal perme-
ability. With no significant difference in HbA1c, inflam-
matory markers or insulin sensitivity between HP and LP
Table 5. RDP and NCBI taxonomy and annotation. When more than one match (99–100%) was found, three accession numbers are listed.
OTU RDP taxonomy NCBI taxonomy Query cover/identity NCBI accession no.
OTU_3 Unclassified Bacteriodes Bacteroides vulgatus ATCC 8482 100/99 NC_009614
OTU_5 Unclassified Enterobacteriaceae Escherichia coli O83:H1 str. NRG 857C, Escherichia
coli str. K-12 substr. MG1655, Escherichia coli
UMN026 chromosome
100/99 NC_017634
NC_000913.3
NC_011751
OTU_7 Unclassified Bacteroidetes No 99–100% match.
OTU_14 Prevotella No 99–100% match.
OTU_20 Unclassified Ruminococceae No 99–100% match.
OTU_44 Clostridium XIVa No 99–100% match.
OTU_50 Blautia No 99–100% match.
OTU_72 Unclassified_Ruminococcaceae No 99–100% match.
OTU_93 Unclassified_Lachnospiraceae No 99–100% match.
OTU_109 Faecalibacterium No 99–100% match.
OTU_129 Parasuttarella Parasutterella excrementihominis YIT 11859
genomic scaffold Scfld40
100/100 NZ_GL883702
OTU_131 Unclassified Lachnospiraceae No 99–100% match.
OTU_151 Unclassified Lachnospiraceae No 99–100% match.
OTU_177 Sutterella Sutterella wadsworthensis 2_1_59BFAA 100/99 NZ_JH815522,
NZ_JH815517,
NZ_JH815517
OTU_180 Ruminococcus Ruminococcus callidus ATCC 27760 100/100 NZ_KI260393
OTU_195 Clostridium XI Clostridium sp. 01 genomic scaffold, scaffold00220 99/99 NZ_HG529443
OTU_329 Unclassified Firmicutes No 99–100% match.
Table 6. Diversity, richness and evenness indices in T2D patients and controls. Values are means and SDs.
T2D patients Controls
LP HP P-value LP HP P-value
n 11 9 16 9
Richness 73.9 (17.9) 80.2 (22.2) 0.456 85.0 (19.9) 76.8 (19.8) 0.328
Evenness 0.70 (0.09) 0.72 (0.02) 0.787 0.70 (0.10) 0.66 (0.09) 0.354
Diversity (Shannon) 3.27 (0.48) 3.32 (0.38) 0.941 3.34 (0.56) 3.12 (0.54) 0.598
Diversity (Simpson) 0.91 (0.05) 0.91 (0.04) 0.520 0.89 (0.10) 0.87 (0.11) 0.337
Diversity (Fisher’s) 24.6 (6.7) 27.1 (10.2) 0.498 30.2 (9.7) 26.3 (9.4) 0.403
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groups, the clinical significance of impaired intestinal bar-
rier function remains uncertain. However, in the healthy
matched controls, increased intestinal permeability was
again associated with elevated Enterobacteriales levels.
We observed a common feature, higher abundance of
the gram-negative bacteria Enterobacteriales in both HP
T2D and control subgroups, suggesting Enterobacteriales
enrichment may be mechanistically linked to increased
colonic permeability irrespective of glucose tolerance sta-
tus. Although gram-negative bacteria have been suggested
to influence gut barrier function by elevating LPS levels
in the gut lumen (Cani et al. 2007), recent studies sug-
gests some gram-negative bacteria (e.g. Akkermansia
muciniphila) may beneficial to the host (Dao et al. 2016;
Plovier et al. 2016). Nonetheless, Proteobacteria and
E. coli enrichment has also been observed in patients with
inflammatory bowel disease which is associated with
increased intestinal permeability. The role of Proteobacte-
ria and E. coli in disease pathogenesis remains uncertain
(Jensen et al. 2015; Matsuoka and Kanai 2015; K€onig
et al. 2016). However, Enterobacteriaceae enrichment has
been observed in other clinical scenarios, such as follow-
ing gastric bypass surgery (RYGB), with no detrimental
effects to the host. In the case of RYGB it even concurs
with resolution of T2D (Graessler et al. 2013).
T2D patients with high colonic permeability had lower
abundances of Selenomonadales and Prevotella. The lower
abundance of Prevotella may be related to the lower car-
bohydrate intake in the HP group. Prevotella is generally
thought to be beneficial to the host (Wu et al. 2011),
although the Prevotella species, P. copri, has been linked
to insulin resistance and glucose intolerance (Pedersen
et al. 2016). The role of Selenomonadales in human health
is unclear, but it contains short-chain fatty acid (SCFA)
producing bacteria which may be beneficial in terms of
gut health (Lecomte et al. 2015).
The overall higher abundance of Enterobacteriales,
unclassified Enterobacteriaceae and E. coli in T2D patients
compared to matched controls, may partly be due to the
use of oral antidiabetic medication (Forslund et al. 2015).
We confirmed this in a retrospective subgroup analysis
comparing metformin with nonmetformin-treated
patients showing that these bacterial taxa were indeed
enriched in metformin-treated patients confirming find-
ings from clinical trials (Napolitano et al. 2014; Wu et al.
2017) and other cross-sectional studies (Karlsson et al.
2013; Forslund et al. 2015). Thus, enrichment of Enter-
obacteria in the T2D group compared with healthy con-
trols may be attributed to metformin treatment and may
not be a characteristic of the intestinal microbiome of
T2D patients per se. This emphasizes the importance of
taking medications into account when comparing popula-
tions with a health condition, with healthy controls.
However, this remains an issue with translating into
human T2D due to the almost ubiquitous use of antidia-
betic medication in patients. Importantly, it must be
noted that in this study the control group showed the
same relationship between Enterobacteriales and intestinal
permeability, without any confounding effects of medica-
tion. Also, a similar proportion of the T2D patients used
metformin in the LP and HP groups. This indicates that
factors other than metformin use may have resulted in
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Figure 5. (A) Bray–Curtis distances in control groups (OW: overweight/obese (n = 13), NW: normal weight (n = 12) and metformin-treated
type 2 diabetes patients (Diabetic – Yes, n = 13) and diabetes patients not treated with metformin (Diabetic – No, n = 7)). The circles show the
95% confidence intervals and the subgroup legends in the plot represent the mean value of each group. Significant differences in bacterial
abundances between groups were found at the order (B), family (C), genus (D), and (E) OTU levels.
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the further increase in Enterobacteriales abundance in the
HP T2D group.
A higher abundance of Blautia in the control HP group
was surprising. The exact composition of this taxa may
be crucial as individuals with normal glucose tolerance
and T2D patients have been reported to display enrich-
ment with different members of Blautia (Zhang et al.
2013). Interestingly metformin use reduced the abun-
dance of a number of bacteria, including Blautia, in high-
fat diet fed mice and this was associated with improved
glucose control (Shin et al. 2014).
No difference in species richness between control and
diabetes patients and between HP and LP groups
(Table 6) were found in this study which is in contrast to
previous findings (Larsen et al. 2010; Forslund et al.
2015). Again, metformin may also have played a role by
modifying the intestinal microbiota in a favorable man-
ner. In the study by Forslund et al. (Forslund et al. 2015)
in those patients taking metformin the gene richness
median and distribution resembled those of the nondia-
betic controls when compared to the nonmetformin-trea-
ted diabetes patients. However, the small sample size of
this study is a limitation and may explain the lack of sig-
nificant differences between groups.
Further limitations to this study are primarily the
hypothesis generating nature of the work and the fact
only men were included in the study. However, in con-
trast to animal models of T2D, medication use is ubiqui-
tous in patients with T2D, especially in the UK with
respect to the prescription of statins and metformin.
Understanding the implication of oral medication and the
interaction between different drugs, the interactions with
diet and the disease process on the microbiome is likely
to be important when conducting future large scale clini-
cal trials.
In conclusion, impaired colonic permeability was asso-
ciated with a modest elevation in fasting glucose and
NEFA in T2D patients. Both in nondiabetic controls and
T2D, high permeability was characterized by a higher
abundance of Enterobacteriales, however, there was no
indication from the measurements conducted in this
study that this increased the risk of metabolic disease in
the control group. Metformin is a clear confounding fac-
tor when comparing T2D patients with healthy controls;
however, despite the increase in Enterobacteria with met-
formin treatment, this did not have a detrimental effect
on the metabolic phenotype.
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